Verséa™ Ophthalmics President, Dr. Rob Sambursky, interviewed by Ophthalmology Times

November 23, 2022by Natasha Svast

Following the American Academy of Ophthalmology (AAO) 2022 Annual Meeting held in Chicago, Verséa Ophthalmics President, Rob Sambursky, MD, was interviewed by Ophthalmology Times to provide an overview of the company and its products.

Dr. Sambursky spoke about BIOVANCE 3L Ocular, a 3-layered decellularized, dehydrated human amniotic membrane (DDhAM) designed for comfort and improved handleability, and Tear-Based Point of Care (T-POC) Quantitative Testing Platform that consists of a portable, multifunctional reader and two tear-based quantitative biomarker test kits: IgE Allergy Test Kit and Lactoferrin Dry Eye Test Kit.

Listen to the Expert Interview and read the transcript here:


About Verséa™ Ophthalmics
Verséa™ Ophthalmics, LLC, a business division of Verséa Health, Inc. (“Verséa”), is one of the fastest growing U.S. healthcare companies on a mission to revolutionize eye care. It is specialized in the sale and distribution of innovative solutions for the diagnosis, treatment, and management of ocular surface diseases. To learn more, visit Verséa™ Ophthalmics webpage